Wedbush Reiterates an 'Outperform' Rating on XenoPort (XNPT); Comments on FDA Advisory Panel Meeting for HORIZANT
Tweet Send to a Friend
Wedbush reiterates an 'Outperform' rating on XenoPort, Inc. (Nasdaq: XNPT), price target $18.
Wedbush analyst says, "We expect XNPT’s stock ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "We expect XNPT’s stock ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
